Drugs / Quadrivalent Inactivated Influenza Vaccine
Quadrivalent Inactivated Influenza Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04697576 | Oct 2021 → Sep 2027 expected | cutaneous melanoma, metastatic melanoma | Carlo Contreras | Recruiting | No outcome recorded |
| Phase 1 | NCT03888989 | Sep 2019 → Dec 2023 | influenza | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT03179761 Comparator | Oct 2017 → Feb 2022 | disease related to hematopoietic stem cell transplant | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT05144945 Comparator | Dec 2021 → Sep 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT03969641 Comparator | Sep 2019 → Sep 2021 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT03502291 Comparator | Aug 2015 → May 2017 | influenza, pneumonia | Liverpool University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent inactivated influenza vaccine | “Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra)” NCT03502291 ↗ |
| Known as | IIV | “Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection” NCT03888989 ↗ |
| Known as | IIV4 | “Quadrivalent inactivated influenza vaccine (IIV4)” NCT05144945 ↗ |
| Modality | Vaccine | “Standard Dose Quadrivalent Influenza Vaccine” NCT03179761 ↗ |
| Route | Intramuscular | “given intramuscularly” NCT03179761 ↗ |